| 6/8/2021 |
Use of External Comparators for Health Technology Assessment Submissions Based on Single-Arm Trials00149-2/abstract) |
valueinhealthjournal.com |
Google Scholar This type of supplementary dataset can be used for naive (unadjusted comparison) or adjusted indirect treatment comparison using STC or MAIC approaches. To describe the landscape for HTA submissions on the basis of SAT data; the use of ECs in this context and their impact on HTA outcomes, we used IQVIA’s HTA Accelerator platform to evaluate HTA reports from 100 HTA agencies across 40 countries published since ... |
| 5/18/2021 |
ISPOR Webinar on Statistical Considerations in Rare Disease Research |
healtheconomics.com |
... rare disease research. Biogen Senior Biostatistician Dr. Shirly Liao and Pediatric Neuromuscular Neurologist Dr. Crystal Proud will share their insights.“The 1-hour educational webinar will focus on the implications of matched adjusted indirect treatment comparison s in rare disease, using SMA as an example. This webinar will provide both statistical and clinical perspective.” Register here.(Source: ISPOR, 2021 ... |
| 5/10/2021 |
Response to the Letter to the Editor Regarding “Intraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison Studies” [Response to Letter] |
dovepress.com |
... missing the point that our analysis sought to compare pneumonia risks between fluticasone and budesonide using data from direct-comparison studies only. To our knowledge, our analysis is the first systematic review of direct treatment comparison studies that addresses an evidence gap highlighted in the 2016 EMA assessment. Notably, the 2016 EMA assessment could not account for some important newer publications, including 2 cohort studies, 3 , 4 a nested case ... |
| 5/1/2021 |
Are You Searching For A Reverse Osmosis Water Treatment Comparison |
canariblogs.com |
May 1, 2021 Leave a comment Home Are You Searching For A Reverse Osmosis Water Treatment Comparison What is a reverse osmosis membrane and how does it work are the very first things you need to understand. It becomes part of a larger reverse osmosis system and a number of these systems are ending up being a growing number of popular for filtering water in home use.But drinking demineralized, distilled ... |
| 3/20/2021 |
DRd vs. VRd as induction therapy for NDMM? - PeopleBeatingCancer |
peoplebeatingcancer.org |
... with R and d please!And that decision is fine. As long as you understand all relevant information. Relevant to you that is. Keep in mind that this is what is called an indirect treatment comparison of chemo combos, regimens. Secondly, this indirect comparison of RVd, DRd, compares your first remission only. I think it is great that a given regimen gives, on average, a longer first remission. However, I ... |
| 3/17/2021 |
Methods: Using a case study in rheumatoid arthritis a Bayesian mi |
pimsignaling.com |
Methods: Using a case study in rheumatoid arthritis a Bayesian mi Posted on by pims5397Methods: Using a case study in rheumatoid arthritis a Bayesian mixed treatment comparison model is fit to estimate the relative efficacy of fiveanti-TNF agents currently licensed in Europe. The model is fit for the continuous HAQ improvement outcome measure and a binary version thereof as well as for the binary ACR response measure ... |
| 11/13/2020 |
Assessing the robustness of network meta-analysis of atypical antipsychotics in the presence of heterogeneity |
rtihs.org |
... METHODS: Data came from recently published Cochrane systematic reviews investigating the effect of atypical antipsychotics in schizophrenia patients. Positive and Negative Syndrome Scale (PANSS) total score endpoint data for trials included in seven direct treatment comparison s (aripiprazole vs. clozapine, quetiapine, risperidone, olanzapine, and ziprasidone; risperidone vs. quetiapine, and olanzapine) were extracted and synthesized using Bayesian random-effects NMA. Relative efficacy was measured using mean difference (MD) in average PANSS total ... |
| 9/11/2020 |
REYVOW™ (lasmiditan) C-V Demonstrated Pain Freedom from Migraine Attacks At 60 Minutes and Up to 48 Hours in New Phase 3 Study |
PR Newswire |
... hour and 2 hours, among others. Patients entered results into an electronic diary at 30 minutes, 60 minutes, as well as 2, 4, 6, 24 and 48 hours after dosing. All of the study's treatment comparison s were prespecified and 18 endpoints were gated, meaning they were set before the study ended and each comparison was reviewed separately in a specified order to verify the accuracy of the study results. REYVOW ... |
| 9/11/2020 |
REYVOW™ (lasmiditan) C-V Demonstrated Pain Freedom from Migraine Attacks At 60 Minutes and Up to 48 Hours in New Phase 3 Study |
BioSpace |
... hour and 2 hours, among others. Patients entered results into an electronic diary at 30 minutes, 60 minutes, as well as 2, 4, 6, 24 and 48 hours after dosing. All of the study's treatment comparison s were prespecified and 18 endpoints were gated, meaning they were set before the study ended and each comparison was reviewed separately in a specified order to verify the accuracy of the study results. REYVOW ... |
| 9/11/2020 |
REYVOW(TM) (lasmiditan) C-V Demonstrated Pain Freedom from Migraine Attacks At 60 Minutes and Up to 48 Hours in New Phase 3 Study |
salesandmarketingnetwork.com |
... hour and 2 hours, among others. Patients entered results into an electronic diary at 30 minutes, 60 minutes, as well as 2, 4, 6, 24 and 48 hours after dosing. All of the study's treatment comparison s were prespecified and 18 endpoints were gated, meaning they were set before the study ended and each comparison was reviewed separately in a specified order to verify the accuracy of the study results.REYVOW SUPERIORITY ... |
| 9/11/2020 |
REYVOW(TM) (lasmiditan) C-V Demonstrated Pain Freedom from Migraine Attacks At 60 Minutes and Up to 48 Hours in New Phase 3 Study - Kokomo Perspective |
tncontentexchange.com |
... hour and 2 hours, among others. Patients entered results into an electronic diary at 30 minutes, 60 minutes, as well as 2, 4, 6, 24 and 48 hours after dosing. All of the study's treatment comparison s were prespecified and 18 endpoints were gated, meaning they were set before the study ended and each comparison was reviewed separately in a specified order to verify the accuracy of the study results. REYVOW ... |
| 9/11/2020 |
REYVOW™ (lasmiditan) C-V Demonstrated Pain Freedom from Migraine Attacks At 60 Minutes and Up to 48 Hours in New Phase 3 Study |
gurufocus.com |
... hour and 2 hours, among others. Patients entered results into an electronic diary at 30 minutes, 60 minutes, as well as 2, 4, 6, 24 and 48 hours after dosing. All of the study's treatment comparison s were prespecified and 18 endpoints were gated, meaning they were set before the study ended and each comparison was reviewed separately in a specified order to verify the accuracy of the study results. REYVOW ... |
| 9/7/2020 |
Intra-articular corticosteroids for treatment of temporomandibular joint internal disorders: protocol for systematic review and network meta-analysis |
BMJ |
... of association across studies. We will carry out meta-analyses at pre-specified follow-up times based on available data. Initially, we will perform pairwise meta-analyses using a random-effects model for every treatment comparison with at least two studies. 18 Next, we will generate and assess the network diagrams to determine if a network meta-analysis is feasible. We will perform the network meta-analysis within a frequentist ... |
| 8/20/2020 |
Agreement between ranking metrics in network meta-analysis: an empirical study |
BMJ |
... on different metrics differ. There are network characteristics that are expected to influence the agreement of treatment hierarchies from different ranking metrics, such as the precision of the included studies and their distribution across treatment comparison s. 4 8 Larger imbalances in precision in the estimation of the treatment effects affects the agreement of the treatment hierarchies from probabilistic ranking metrics, but it is currently unknown whether in practice these imbalances ... |
| 8/14/2020 |
Covid-19 Lies, Damn Lies. Come to Berlin 29.08.2020 and join the Intern. Meeting to bring down Shutdown now |
Wordpress.com |
... guess. Nefarious motives are not necessary for these problems to occur. […] But if leaders, commentators, academics, and clinicians cannot restrain the rush to judgment in the absence of reliable evidence, the proliferation of observational treatment comparison s will hinder the goal of finding effective treatments for COVID-19 — and a great many other diseases. Thus, we see that the WHO and local public health officials are hindering advancement, by promoting ... |
| 8/5/2020 |
DULERA (mometasone furoate and formoterol fumarate dihydrate) aerosol [Merck Sharp & Dohme Corp.] |
National Institutes of Health |
... component to DULERA. Patients receiving DULERA 100 mcg/5 mcg had significantly higher increases from baseline at Week 12 in mean FEV 1 AUC (0-12 hr) compared to mometasone furoate 100 mcg (the primary treatment comparison ) and vs. placebo (both p 0.001) ( Figure 1 ). These differences were maintained through Week 26. Figure 1 shows the change from baseline post-dose serial FEV 1 evaluations in Trial 1. Figure 1 Trial ... |
| 7/23/2020 |
EVERSANA's Data & Analytics platform to be used by ICER to conduct indirect treatment comparisons to support value assessments |
PR Newswire |
EVERSANA's Data & Analytics platform to be used by ICER to conduct indirect treatment comparisons to support value assessments 00 CHICAGO EVERSANA™ , the leading provider of global commercial services to the life sciences industry, today announced a partnership with the Institute for Clinical and Economic Review (ICER) to advance standards for the usage of transparent, replicable and robust indirect treatment comparisons in health technology assessments. ICER is an independent nonprofit research ... |
| 7/23/2020 |
EVERSANA’s Data & Analytics platform to be used by ICER |
pharmalive.com |
Analytics , Business , Data , Data Analysis , Health Economics and Outcomes Research (HEOR) , Health Technology , Partnerships , U.S. Institute for Clinical and Economic Review (ICER) EVERSANA’s Data & Analytics platform to be used by ICER to conduct indirect treatment comparison s to support value assessments CHICAGO , July 23, 2020 /PRNewswire/ — EVERSANA™ , the leading provider of global commercial services to the life sciences industry, today announced a partnership with the Institute for Clinical and Economic Review ... |
| 7/23/2020 |
EVERSANA's Data & Analytics platform to be used by ICER to conduct indirect treatment comparisons to support value assessments |
tncontentexchange.com |
EVERSANA's Data & Analytics platform to be used by ICER to conduct indirect treatment comparisons to support value assessments By Eversana Save CHICAGO , July 23, 2020 /PRNewswire/ -- EVERSANA™ , the leading provider of global commercial services to the life sciences industry, today announced a partnership with the Institute for Clinical and Economic Review (ICER) to advance standards for the usage of transparent, replicable and robust indirect treatment comparisons in health technology assessments ... |
| 7/23/2020 |
EVERSANA's Data & Analytics platform to be used by ICER to conduct indirect treatment comparisons to support value assessments |
BioSpace |
... of global commercial services to the life sciences industry, today announced a partnership with the Institute for Clinical and Economic Review (ICER) to advance standards for the usage of transparent, replicable and robust indirect treatment comparisons in health technology assessments ... |